Clinical Policy: Abatacept (Orencia) Coverage Criteria
Customize your policy alerts
Sign up for Peach State Health Plan Policy CP.PHAR.241 alerts
Get alerted when Policy CP.PHAR.241 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, exclusions, dosing, and therapeutic alternatives for abatacept (Orencia) for Peach State Health Plan members across indicated conditions and provides appendices with scoring systems and dose rounding guidance.
No material clinical or coverage changes in this revision.
Coverage Criteria — Indications, Dosing, and Exclusions
Dosing / Administration
Dosing regimens and maximum doses by indication and weight/age
For RA: if a single IV loading dose is given, start first SC injection within one day of the IV dose.
Maximum SC dose listed as 125 mg/week.
pJIA-specific bands align with these pediatric SC doses.
Maximum IV dose 1,000 mg every 4 weeks.
Maximum dose 1,000 mg per dose.
Coverage is limited to FDA‑approved indications and other uses explicitly addressed in this policy. Non‑FDA approved indications that are not listed in this policy will not be authorized unless the provider supplies sufficient documentation of efficacy and safety in accordance with the Peach State off‑label use policy CP.PMN.53. Requests for off‑label uses without adequate supporting documentation may be denied.
The policy explicitly prohibits combination therapy of abatacept with other biologic DMARDs or with Janus kinase inhibitors. This prohibition has been reiterated across policy sections (Sections I–III) and in recent reviews; requests for combination use with a bDMARD or a JAK inhibitor are not authorized and may be denied.
Use of abatacept in combination with other biologic DMARDs or potent immunosuppressants is considered not authorized due to additive immunosuppression and increased risk of neutropenia and serious infections. Examples of agents that must not be used concurrently with abatacept include, but are not limited to, TNF antagonists (e.g., Cimzia, Enbrel, Humira and biosimilars, Remicade and biosimilars, Simponi), interleukin agents (e.g., Actemra, Arcalyst, Bimzelx, Cosentyx, Ilaris, Ilumya, Kevzara, Kineret, Omvoh, Siliq, Skyrizi, Spevigo, Stelara, Taltz, Tremfya), JAK inhibitors (e.g., Cibinqo, Olumiant, Rinvoq, Xeljanz), anti‑CD20 agents (e.g., Rituxan), integrin receptor antagonists (Entyvio), tyrosine kinase 2 inhibitors (Sotyktu), sphingosine‑1‑phosphate receptor modulators (Velsipity), and other selective co‑stimulation modulators. Concurrent administration with these agents is not authorized.
Initial / Induction Therapy Requirements
Initial/induction therapy
Induction and pediatric/adult initial dosing per indication and weight:
Follow indication-specific loading schedules.
Document weight and age to support dosing.
Maximum IV 1,000 mg every 4 weeks.
Maximum 1,000 mg/dose.
Initial Therapy
Initial dosing regimens vary by indication, age, and weight.
Follow indication-specific loading schedules.
If IV loading given for RA, begin SC within one day.
Maintenance and Continuation Therapy
Maintenance dosing
Maintenance dosing after initiation/induction:
See Appendix V/J for full regimens and pediatric dosing.
Continuation Therapy
Continued therapy considerations and historical updates
Exact continued criteria and any removed items are documented in the policy revision history.
Step Therapy and Therapeutic Alternatives
| Step | Requirement | Notes |
|---|---|---|
| 1 | Use of listed therapeutic alternatives (conventional DMARDs, TNF inhibitors, other biologics) may be preferred prior to initiation of abatacept (Orencia). | Appendix B provides specific alternative agents and dosing regimens; some alternatives may not be formulary for all lines of business and may require prior authorization. |
| Step | Requirement | Notes |
|---|---|---|
| 1 | Follow Section III step therapy and redirection rules (including use of preferred agents and biosimilars where required) before abatacept when applicable. | Policy includes redirection and TNFi bypass rules (e.g., TNFi bypass if history of failure of two TNF blockers) and lists preferred adalimumab products and other redirect options in Section III and Appendix B. |
Coding and Billing Guidance
| J0129 | Injection, abatacept, 10 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered) |
Quantity Limits and Dosing Caps
Provider Actions, Authorization & Documentation
Prior authorization required; combination use prohibited
Prior authorization is required for abatacept and combination use with other biologic DMARDs or potent immunosuppressants is explicitly not authorized; requests for combination therapy will not be approved due to additive immunosuppression and increased infection risk.
- Prior authorization required in alignment with formulary/non‑formulary and off‑label policies.
- Combination use with bDMARDs or potent immunosuppressants (e.g., TNF antagonists, interleukin agents, JAK inhibitors, anti‑CD20 agents, integrin antagonists, TK2 inhibitors, S1P modulators) is not authorized.
Coding/PA note — use J0129 under physician supervision
When abatacept is administered under the direct supervision of a physician, report HCPCS code J0129 (injection, abatacept, 10 mg); note that code listing in the policy is informational and does not guarantee coverage — follow current professional coding guidance.
- Use J0129 when drug is administered under direct physician supervision (not for self‑administered formulations).
- Inclusion or exclusion of codes in this policy does not guarantee coverage; providers must reference up‑to‑date coding guidance when submitting claims.
Therapeutic alternatives may be preferred and require PA
Therapeutic alternatives listed in Appendix B may be preferred; some alternatives may themselves require prior authorization per formulary or line‑of‑business policies.
- Appendix B provides a listing of preferred alternative therapies; these agents may not be formulary for all lines of business.
- Some alternative drugs may require their own prior authorization per the applicable formulary (see CP.PMN.255/CP.PMN.16 as applicable).
Follow step therapy/redirection rules in Section III
Follow Section III step therapy and redirection rules when applicable; the policy includes redirection and TNFi bypass provisions that providers must follow during prior authorization review.
- Policy contains redirection to other agents (e.g., Actemra, Olumiant) and TNFi bypass rules for members with prior failures per Section III.
- Providers must follow Section III step and redirection requirements before abatacept when those rules apply.
Off‑label requests must follow CP.PMN.53 and include supporting documentation
If the requested use is not listed in Section III and other formulary policies do not apply, providers must refer to the off‑label use policy CP.PMN.53 (for Medicaid) and supply sufficient documentation of efficacy and safety as required by that off‑label policy.
- Requests for non‑FDA approved indications not addressed in this policy require documentation per CP.PMN.53.
- Insufficient off‑label documentation may result in denial (see off‑label policy requirements).
Document weight, age, and product formulation
Document the patient’s weight and age and record the product formulation (vial, prefilled syringe, autoinjector) to support weight‑based IV dosing and pediatric SC dosing at the time of prior authorization and claim submission.
- Provide weight and age to justify selection of the correct weight band (e.g., pediatric 10 to <25 kg, 25 to <50 kg, ≥50 kg; adult bands <60 kg, 60–100 kg, >100 kg).
- Record the formulation used (single‑use IV vial vs prefilled syringe or autoinjector) since J0129 is not appropriate for self‑administered products.
Non‑FDA/non‑listed uses without adequate documentation may be denied
Requests for non‑FDA approved indications or other uses not addressed in the policy without sufficient supporting documentation may be denied per the off‑label use policy.
- Non‑FDA indications not addressed in this policy require sufficient documentation of efficacy and safety per CP.PMN.53; lacking that, requests may be denied.
- Combination use with other bDMARDs or potent immunosuppressants is explicitly not authorized and may be denied.
Code listings are informational — verify coding guidance before claims
Inclusion or exclusion of specific billing codes in this policy does not guarantee coverage; claims must follow current professional coding guidance and may be denied if coding rules are not followed.
- Policy code listings are informational only; verify coding guidance before claim submission.
- J0129 may be used for physician‑administered abatacept but is not for self‑administered formulations.
Site of Care and Administration Setting
IV administration expected in infusion setting; SC may be clinic or home
IV abatacept dosing is weight‑based and expected to be given in an infusion setting; SC dosing may be given in clinic or at home per site rules.
- IV administration implied by weight‑based IV dosing and expected in an infusion center.
- SC dosing may be administered in clinic or at home.
Biosimilar and Alternative Examples
Preferred adalimumab products/biosimilars listed as redirect options
Appendix and update notes list preferred adalimumab products and biosimilars (examples include Yusimry, Hadlima, adalimumab‑fkjp, adalimumab‑adbm, Simlandi, unbranded adalimumab‑aaty). Use of a preferred adalimumab product may be required as a redirect prior to abatacept for some indications.
- Preferred adalimumab examples include Yusimry, Hadlima, adalimumab‑fkjp, adalimumab‑adbm, Simlandi, and unbranded adalimumab‑aaty.
- Policy changes replaced previous redirection to Enbrel with requirement for use of one adalimumab product in some indications.
Selected Abbreviations and Acronyms
Background and Appendices
Appendices to this policy include clinical scoring tools used to assess disease activity and support treatment decisions and continued therapy reviews. Included instruments are the ACR 2010 rheumatoid arthritis criteria, the CDAI, the RAPID3, and the cJADAS‑10. These tools and related appendices provide definitions (e.g., failure of methotrexate/DMARD), scoring thresholds, and guidance referenced elsewhere in the policy for initiation and continuation of abatacept.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.